Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment efficacy of BCAA on cognitive function and driving skill in patients with minimal hepatic encephalopathy
KCT0003581Phase 4Not yet recruiting
- Sponsor
- Samil Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Branchamin in chronic liver disease (CLD), Cirrhosis, hepatic encephalopathy (HE), sponsored by Samil Pharmaceutical Co., Ltd.. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
Branchamin
03
Conditions
chronic liver disease (CLD)Cirrhosishepatic encephalopathy (HE)
Beyond the preview
Go deeper on KCT0003581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003581.